Spark Therapeutics is a Philadelphia-based gene therapy company founded in 2013 with roots at Children's Hospital of Philadelphia (CHOP). Spark developed Luxturna (voretigene neparvovec-rzyl), the first FDA-approved gene therapy for a genetic disease in the United States, approved in December 2017 for the treatment of inherited retinal disease… - View it on GitHub